Artificial Heart Market By Type (Total Artificial Hearts, Left Ventricular Assist Devices ), Technology, End-User (Hospitals, Ambulatory Surgical Centers ), & Region for 2026-2032

Artificial Heart Market Valuation - 2026-2032

The demand for artificial hearts is quickly expanding owing mostly to the rising global frequency of cardiovascular disorders. Heart failure which is frequently caused by illnesses such as coronary artery disease, high blood pressure, and heart attacks is growing increasingly widespread as the world's population ages and lifestyle-related health issues increase. Unfortunately, the supply of donor hearts for transplantation is limited resulting in a considerable disparity between the number of people in need and the organs available by enabling the market to surpass a revenue of USD 2.59 Billion valued in 2024 and reach a valuation of around USD 7.34 Billion by 2032.

Technological breakthroughs are also contributing significantly to the growing demand for artificial hearts. Materials science, downsizing, and biocompatibility advancements are paving the way for more sophisticated artificial hearts that can better replicate natural cardiac activities. These innovations improve patient's quality of life by minimizing problems and increasing the device's lifespan by enabling the market to grow at a CAGR of 13.92% from 2026 to 2032.

Artificial Heart Market: Definition/ Overview

An artificial heart is a mechanical device that replaces a failing human heart, either temporarily or permanently, to keep blood flowing and oxygen delivered to the body. It is primarily used in individuals with severe heart diseases including as end-stage heart failure in which the heart is no longer able to efficiently pump blood. The artificial heart replicates the natural heart's function by pumping blood through the circulatory system ensuring that essential organs receive the oxygen and nutrition they require to function.

The artificial heart is a groundbreaking medical device that replaces the function of a failing human heart providing life-saving support to patients suffering from serious cardiac diseases. One of the key uses for artificial hearts is as a bridge to heart transplantation. An artificial heart can temporarily replace the failing organ in individuals with end-stage heart failure in which the heart can no longer adequately pump blood. This enables patients to survive while awaiting a donor heart for transplantation.

The future usage of mechanical hearts has the potential to change cardiology providing new hope to patients with serious cardiac diseases. As the global burden of heart disease rises, artificial hearts are becoming an increasingly important option for patients who are unable to receive heart transplants due to a lack of donor organs or other medical reasons. These devices are designed to perform similarly to a natural heart moving

blood throughout the body and prolonging life when the patient's own heart is no longer functioning.

Will the Rising Incidence of Cardiovascular Diseases Drive the Artificial Heart Market?

The increasing incidence of cardiovascular diseases (CVDs) is a major driver of the artificial heart market. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of mortality worldwide, killing an estimated 17.9 million people each year. This accounts for 31% of all deaths globally. CVD prevalence has continuously increased, particularly in low- and middle-income nations which account for more than 75% of CVD deaths. In the United States alone, the Centers for Disease Control and Prevention (CDC) says that heart disease is the leading cause of death accounting for around 655,000 fatalities yearly or one in every four deaths.

This worrying rise in CVD prevalence is predicted to increase demand for artificial hearts as a life-saving treatment for individuals with end-stage heart failure. The National Heart, Lung, and Blood Institute (NHLBI) estimates that roughly 6.2 million adults in the United States have heart failure with projections indicating that this figure could rise to over 8 million by 2030. Furthermore, the United Network for Organ Sharing (UNOS) reports that as of 2021, there were over 3,500 people on the waiting list for a heart transplant in the United States. Given the ongoing paucity of donor hearts, artificial hearts serve as an important bridge-to-transplant option or, in certain situations, a destination therapy.

Will the High-Cost Hamper the Artificial Heart Market?

The high cost of artificial hearts poses a substantial barrier to market expansion, potentially limiting adoption and accessibility. According to the National Institute of Health (NIH), the overall cost of an artificial heart transplant including the device and related medical care can range between $150,000 and $500,000. Many patients and healthcare systems, particularly in developing countries or locations with low healthcare resources are unable to afford mechanical hearts due to the significant financial load. According to the Centers for Medicare and Medicaid Services (CMS), while they cover certain ventricular assist devices (VADs) for qualifying beneficiaries, full artificial heart transplants are not usually reimbursed, further limiting access for elderly patients who frequently require such operations.

The high cost has an impact not just on patient access but also on research and development in the sector. The Food and Drug Administration (FDA) has claimed that the long clinical trials required for artificial heart approval can cost manufacturers hundreds of millions of dollars discouraging some companies from joining the market or developing novel designs. This expensive barrier to entry may stifle technological developments and hinder competition, thus maintaining high costs in the long run. Furthermore, the National Heart, Lung, and Blood Institute (NHLBI) has stated that, while government funding for artificial heart research has increased in recent years, it remains insufficient to encourage rapid innovation and cost reduction in the sector.

Category-Wise Acumens

Will Broader Application and Widespread Adoption Drive Growth in the Type Segment?

Left Ventricular Assist Devices (LVADs) are in a dominant position owing to their broad application and widespread adoption in treating patients with severe heart failure. LVADs are intended to support the left ventricle, the heart's major pumping chamber responsible for delivering oxygen-rich blood to the body. These devices are frequently utilized as a bridge to heart transplantation providing critical-care patients with the essential assistance while they wait for a donor heart. Furthermore, LVADs are increasingly being used as destination therapy for patients who are not candidates for transplantation due to age, comorbidities, or other criteria.

The incidence of heart failure, particularly among the elderly has contributed to the demand for LVADs. As the world's population ages, the prevalence of heart failure is predicted to climb creating a higher demand for advanced treatments such as LVADs. Furthermore, technological advances in LVAD design have resulted in smaller, more efficient, and easier-to-implant devices lowering surgical risks while increasing patient outcomes. Wireless power transfer and better biocompatible materials have improved the safety and endurance of LVADs making them more appealing to patients and healthcare professionals.

Will the Ongoing Research and Development Drive the Technology Segment?

Continuous flow technology has emerged as the dominant force, owing to major improvements over prior pulsatile flow systems. Continuous flow artificial hearts use a continuous, non-pulsatile mechanism to pump blood throughout the body providing several significant benefits that make them the favored choice in the medical profession. One of the key advantages is their tiny size which enables easier implantation in a broader range of patients including those with lower body proportions. This downsizing has made the technology more accessible and minimally intrusive resulting in better patient outcomes and shorter recovery periods.

Furthermore, continuous flow devices are noted for their long lifespan. Because they work on a consistent, continuous basis without the need for moving elements to contract and expand like normal heartbeats, Continuous flow technology not only leads the artificial heart market but it also symbolizes the future of cardiac support systems. Continuous research and development in this area improves the performance and reliability of these devices, further distinguishing them from their pulsatile predecessors. The medical community's choice of continuous flow devices is also influenced by the larger trend toward minimally invasive and long-lasting cardiac care solutions. This trend is likely to continue as technology advances ensuring that continuous flow artificial hearts stay at the forefront of life-saving cardiac procedures.

Country/Region-wise Acumens

Will Advanced Healthcare Infrastructure Drive the Market in the North American Region?

The North American region, particularly the United States and Canada is well-positioned to dominate the artificial heart industry due to its advanced healthcare infrastructure and significant investments in medical technology. North America, notably the United States, has some of the world's most complex healthcare systems with cutting-edge medical facilities, robust research and development skills, and significant investment in healthcare technology. These variables work together to produce an atmosphere that encourages the acceptance and development of advanced medical equipment such as artificial hearts.

The North American market benefits from an established regulatory structure that facilitates the approval and marketing of breakthrough medical innovations. The US Food and Drug Administration (FDA) is an important player in this process ensuring that new medical devices fulfill high safety and efficacy requirements before they are released to the market. This stringent approval process, though difficult, ultimately contributes to the trust and confidence that healthcare providers and patients have in these devices. The availability of significant funding and payment options for sophisticated cardiac treatments makes artificial hearts more accessible to patients, which drives market growth. Furthermore, the region's aging population, which is increasingly susceptible to heart-related ailments raises the need for effective cardiac support systems.

Will the Demand for Advanced Cardiac Therapies Drive the Market in the Asia Pacific Region?

The Asia Pacific region is expected to be the fastest-growing artificial heart market owing to increased cardiovascular disease prevalence and healthcare expenditure. This rapid expansion is primarily attributable to the vast population base, improved healthcare infrastructure, and increased awareness of innovative cardiac therapy in nations such as China, Japan, and India.

The demand for innovative cardiac therapy in Asia Pacific is projected to drive the artificial heart industry. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of mortality worldwide claiming an estimated 17.9 million lives per year. In the Western Pacific region which includes many Asian countries, cardiovascular diseases account for 35% of all deaths.

The increased frequency of CVD combined with an aging population is driving significant demand for sophisticated cardiac treatments including artificial hearts. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), Asia and the Pacific's elder population is predicted to grow from 630 million in 2020 to approximately 1.3 billion by 2050. This demographic transition is projected to increase the incidence of heart failure, and thus the demand for artificial hearts. Furthermore, increased healthcare spending in the region is encouraging the use of modern medical technologies.

Competitive Landscape

The Artificial Heart Market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the artificial heart market include:

• Jarvik Heart, Inc.
• BiVACOR, Inc.
• CARMAT SA
• SynCardia Systems, LLC
• MyLVAD
• Thoratec Corporation
• Cirtec
• Abbott
• ON-X LIFE TECHNOLOGIES, INC.
• ABIOMED
• Cleveland Heart, Inc.
• Tianjin Medical
• Braile Biomedica
• Edwards Lifesciences
• R. Bard, Inc.
• Terumo Corporation
• MAQUET GmbH & Co. KG
• Sorin Group
• Medtronic, Inc.

Latest Developments

• In September 2023, Abbott (NYSE: ABT) announced the completion of its acquisition of Bigfoot Biomedical, a market leader in the creation of smart insulin control devices for diabetics.

Artificial Heart Market, By Category

• Type:
• Total Artificial Hearts (TAH)
• Left Ventricular Assist Devices (LVAD)
• Technology:
• Continuous Flow Technology
• Pulsatile Flow Technology
• End-User:
• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa